JCR Pharmaceuticals Co., Ltd.
JCR Pharma 2026 Financial Results | Revenue increased by 40.3 billion yen, net profit 2.1 billion yen
JCR Pharma achieved sales of 40.3 billion yen (up 21.9% YoY) for the fiscal year ending March 2026, and recovered to a net profit of 2.1 billion yen. Increased R&D expenses and progress in new drug development contributed to the performance. The company anticipates continued sales growth and proactive investments in the next period to aim for long-term growth.
Key Figures
- Net Sales: 40,319 million yen (up 21.9% YoY)
- Net Income Attributable to Owners of Parent: 2,178 million yen (turned positive)
- R&D Expenses: 16.761 billion yen (up 1.33 billion yen YoY)
AI要約
Overview of Financial Performance
JCR Pharma recorded net sales of 40.3 billion yen (up 21.9% YoY) for the fiscal year ending March 2026, and turned profitable with a net income of 2.1 billion yen. Contributing factors include strong sales of the enzyme therapy drug "Izarga®" for mucopolysaccharidosis and progress in new drug development. R&D expenses increased, and the company plans to continue expanding sales and making active investments to achieve long-term growth.
Future Outlook and Shareholder Returns
For the next fiscal year ending March 2027, sales are expected to reach 45.7 billion yen (up 13.3% YoY), with R&D expenses increasing to 19.3 billion yen. Operating profit is forecasted at 1.1 billion yen, and the company plans to maintain a dividend of 20 yen. By pursuing long-term research investments and new drug development, the company aims for sustainable growth.
JCR Pharma Co., Ltd.
Company overview · Stock price · Financial data · All IR
